Fig. 1From: Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational studyThe scheme of the clinical trial design. TKI tyrosine kinase inhibitor, ctDNA circulating tumor DNA, EGFR epidermal growth factor receptor, ARMS amplification refractory mutation system, ddPCR droplet digital PCRBack to article page